Drug Profile
Elifactant - Chiesi Farmaceutici
Alternative Names: CHF-5633Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Chiesi; Karolinska Institute; Swedish University of Agricultural Sciences
- Developer Chiesi
- Class Pulmonary surfactants
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neonatal respiratory distress syndrome
Most Recent Events
- 30 Jul 2019 No development reported - Phase-I/II for Neonatal respiratory distress syndrome in United Kingdom (Intratracheal)
- 24 May 2018 Chiesi Farmaceutici completes a phase II trial in Neonatal respiratory distress syndrome in USA (Intratracheal) (NCT02452476)
- 01 Jan 2016 Phase-II clinical trials in Neonatal respiratory distress syndrome in USA (Intratracheal) (NCT02452476)